Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

Also called NCT03067688

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 202 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03067688
Other papers using this trial's data
  • Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia Journal of clinical hypertension (Greenwich, Conn.), 2020-10 DOI, PubMed 32937023, PMC7692919 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03067688. Randomized; double masking; primary purpose treatment. Start 2017-04-11 (actual); primary completion 2018-03-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia
Condition
Hypertension
Condition
Hyperlipidemia
Intervention (Drug)
Temisartan+Amlodipine+Rosuvastatin (Combination drug)
Intervention (Drug)
Temisartan+Amlodipine
Intervention (Drug)
Temisartan+Rosuvastatin
Lead sponsor
Yuhan Corporation (class: industry)

Record details

Record id
cardio:ct-nct03067688
Content hash
0aeac6c2826f428b5e4e7add4f07123c78fc603628da58b4eca3c83af9cb8368